Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

Idiopathic Inflammatory Myopathies: A 2016 Update

Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune diseases, primarily affecting the skeletal muscles, which cause predominant proximal muscle weakness.
CME credit is no longer available for this conference.

Course Authors

Julie J. Paik, M.D.. M.H.S. and Lisa Christopher-Stine, M.D., M.P.H.

Release Date: 11/15/2016

 
Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Distinguish the different forms of myositis based on pattern of weakness, EMG findings, MRI findings and muscle histopathology;

  • List the most common myositis-associated and specific antibodies in polymyositis, dermatomyositis, immune mediated necrotizing myopathy and inclusion body myositis;

  • Recognize that a statin can trigger an immune mediated necrotizing myopathy;

  • Describe the autoantibodies that can characterize specific subgroups of myositis and reveal a specific clinical phenotype associated with the myositis-specific or associated antibody.

 

TERMS AND CONDITIONS

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms.

Courses You Might Like

Fibromyalgia: Current State of the Art

women. Despite its high burden, the pathophysiology of FM remains poorly understood, leading to challenges in diagnosis and treatment. Over the past decade, research has advanced our understanding of FM. The disorder is now linked to central nervous system (CNS) dysfunction, altered neurotransmitter activity and immune dysregulation.
Authors: Danilo De Gregorio, PharmD, Ph.D.
More

Treatment of Idiopathic Inflammatory Myopathy

With few FDA-approved medications available, the treatment of myositis is challenging.
Authors: Siamak Moghadam-Kia, M.D., Rohit Aggarwal, M.D. and Chester V. Oddis, M.D.
More

The Current Treatment of Lupus Nephritis

Despite therapeutic advances, lupus nephritis continues to lead to significant morbidity and mortality with 10-15% of patients progressing to end-stage renal disease requiring renal replacement therapy.
Authors: Saakshi Khattri, M.D., and Peter Barland, M.D
More

Palindromic Rheumatism

An episodic recurring arthritis with unknown etiopathogenesis.
Authors: Sahitya Mallipeddi, M.D., Raghu Maddela, M.D., and Peter Barland, M.D.
More

Immunoglobulin G4-related Sclerosing Syndrome

This month, Peguy Saad, M.D., and Peter Barland, M.D., discuss

cells. It is also known for its dramatic response to steroids. The recent identification of IgG4 in the affected tissues of many chronic inflammatory syndromes has led to the recognition of a new clinicopathological entity — IgG4 RSS. Prior to the discovery of IgG4 RSS as a multiorgan disorder, many
Authors: Peguy Saad, M.D., and Peter Barland, M.D.
More

Hemophagocytic Syndrome in Rheumatic Diseases

This month, Arlene Tan Tieng, M.D., Irene Blanco, M.D., and Peter Barland, M.D., discuss

abdomen and no rash, lymphadenopathy or synovitis. He was found to be pancytopenic with a WBC of 2600/mm3, an absolute neutrophil count of 1700/mm3, a hemoglobin of 8.9 gm/dL and platelets of 22,000/mm3 with schistocytes seen on the peripheral blood smear. His International Normalized Ratio (INR) was increased at
Authors: Arlene Tan Tieng, M.D., Irene Blanco, M.D., and Peter Barland, M.D.
More